AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7696942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 2416
Study 2577441 — intervention group
Group type: COMPARATOR
Intervention: Chlordesmethyldiazepam 0.1 mg/kg‐1 i.v. (group C)
Number of subjects: 16
Study 2577441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiopental 5 mg/kg‐1 i.v. (Group T)
Number of subjects: 16
Study 389815 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimazine (410 mg sulphadiazine plus 90 mg trimethoprim)
Number of subjects: 79
Study 389815 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim)
Number of subjects: 79
Study 389815 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimazine and Co-trimoxazole
Number of subjects: 79
Study 31912157 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN α‐2a for 48 weeks
Number of subjects: 133
Study 30445572 — intervention group
Group type: EXPERIMENTAL
Intervention: Low suction (-2 cmH2O)
Number of subjects: 228
Study 30445572 — intervention group
Group type: COMPARATOR
Intervention: High suction (-10 cmH2O)
Number of subjects: 228
Study 29074717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine-70% isopropyl alcohol (CHX-IA)
Number of subjects: 304
Study 27515572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic emulsion (CE)
Number of subjects: 85
Study 27515572 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronate sodium (HS)
Number of subjects: 85
Study 25151583 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic treatment with premolar extraction (n = 30)
Number of subjects: 129
Study 25151583 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic treatment without premolar extraction (n = 34)
Number of subjects: 129
Study 25151583 — intervention group
Group type: COMPARATOR
Intervention: Control group, no orthodontic treatment (n = 65)
Number of subjects: 129
Study 22090280 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular 8-hour night sleep
Number of subjects: 14
Study 22090280 — intervention group
Group type: COMPARATOR
Intervention: Continuous wakefulness
Number of subjects: 14
Study 19617465 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (50 mg or 100 mg every 4 weeks)
Number of subjects: 337
Study 17877100 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone status, gynecologic surgery, alcohol intake, age, educational attainment
Number of subjects: 2
Study 17877100 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and fluid intake
Number of subjects: 2
Study 17877100 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 2
Study 15195794 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced memory training
Number of subjects: 26
Study 15195794 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback memory training
Number of subjects: 26
Study 15195794 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized memory training
Number of subjects: 26
Study 15195794 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual presentation memory training
Number of subjects: 26
Study 15195794 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 11596851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 0
Study 11596851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11596851 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 10023274 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 40
Study 10023274 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 7803065 — intervention group
Group type: EXPERIMENTAL
Intervention: Health screening and promotion services offered to experimental group
Number of subjects: 1900
Study 7803065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health screening and promotion services)
Number of subjects: 1900
Study 7803065 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at health screening services
Number of subjects: 1900
Study 3289931 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem alone
Number of subjects: 14
Study 3289931 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 14
Study 3289931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diltiazem plus digoxin
Number of subjects: 14
Study 29793716 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning (BL) approach in pharmacy seminar course
Number of subjects: 72
Study 28267480 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg betrixaban
Number of subjects: 2506
Study 28267480 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg betrixaban
Number of subjects: 2506
Study 28267480 — intervention group
Group type: COMPARATOR
Intervention: enoxaparin
Number of subjects: 2506
Study 26032626 — intervention group
Group type: EXPERIMENTAL
Intervention: LACAeP (Liverpool ADR Causality Assessment e-learning Package)
Number of subjects: 57
Study 26032626 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAT (Liverpool Causality Assessment Tool)
Number of subjects: 57
Study 26032626 — intervention group
Group type: EXPERIMENTAL
Intervention: LACAeP
Number of subjects: 57
Study 26032626 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 57
Study 21736887 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (7 mg/kg)
Number of subjects: 0
Study 21736887 — intervention group
Group type: COMPARATOR
Intervention: Saline treatment (control)
Number of subjects: 0
Study 18426998 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐l‐arginine (lower dose)
Number of subjects: 14
Study 18426998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25 mg PO)
Number of subjects: 14
Study 18426998 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐l‐arginine (infusion)
Number of subjects: 14
Study 18426998 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (equipressor doses)
Number of subjects: 14
Study 16568340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration muscle exercise (RVE, 2x6 min daily)
Number of subjects: 20
Study 16568340 — intervention group
Group type: EXPERIMENTAL
Intervention: RVE training
Number of subjects: 20
Study 16568340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RVE)
Number of subjects: 20
Study 12731640 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 9
Study 12731640 — intervention group
Group type: EXPERIMENTAL
Intervention: vigabatrin
Number of subjects: 9
Study 12731640 — intervention group
Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 9
Study 16084853 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Number of subjects: 14
Study 16084853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10612553 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) infusion
Number of subjects: 35
Study 10612553 — intervention group
Group type: COMPARATOR
Intervention: Control (physiological saline)
Number of subjects: 35
Study 8565026 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ 800 mg/d
Number of subjects: 40
Study 8565026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2201541 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release carbamazepine (SR) preparation
Number of subjects: 21
Study 2201541 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbamazepine (C) preparation
Number of subjects: 21
Study 7302260 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg 15(R)-15-methyl prostaglandin E2 (PG)
Number of subjects: 40
Study 7302260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 40
Study 31119716 — intervention group
Group type: EXPERIMENTAL
Intervention: LY IGlar
Number of subjects: 493
Study 31119716 — intervention group
Group type: COMPARATOR
Intervention: IGlar
Number of subjects: 493
Study 28865815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs only (Group A)
Number of subjects: 400
Study 28865815 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for 3 days + anti-inflammatory drugs (Group B)
Number of subjects: 400
Study 28865815 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of antibiotic 1 hour before extraction + anti-inflammatory drugs (Group C)
Number of subjects: 400
Study 28865815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash for 7 days + anti-inflammatory drugs (Group D)
Number of subjects: 400
Study 25919834 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired insight into delusions (assessed using the Delusion Assessment Scale)
Number of subjects: 259
Study 25919834 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired insight into delusions (assessed after 3 weeks of treatment)
Number of subjects: 259
Study 25919834 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired insight into delusions (assessed after 6 weeks of treatment)
Number of subjects: 259
Study 25919834 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired insight into delusions (assessed after 8 weeks of treatment)
Number of subjects: 259
Study 23562130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 36
Study 23562130 — intervention group
Group type: COMPARATOR
Intervention: Exemestane (EXE)
Number of subjects: 36
Study 23562130 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TAM and EXE
Number of subjects: 36
Study 21182118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU)
Number of subjects: 0
Study 21182118 — intervention group
Group type: COMPARATOR
Intervention: SHAM Acupuncture
Number of subjects: 0
Study 19609738 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels ≥7 mg/L
Number of subjects: 561
Study 19609738 — intervention group
Group type: COMPARATOR
Intervention: CRP levels <7 mg/L
Number of subjects: 561
Study 19609738 — intervention group
Group type: EXPERIMENTAL
Intervention: Full range of CRP values
Number of subjects: 561
Study 17511751 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14734789 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic remedies (LM 1/50,000)
Number of subjects: 62
Study 14734789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 11497201 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant Hypertension (MHT)
Number of subjects: 102
Study 11497201 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated nonmalignant essential hypertension (EHT)
Number of subjects: 102
Study 11497201 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 102
Study 9574454 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CCr) predicted from plasma creatinine (PCr) and body composition analysis (FFM and BCM) using electrical impedance
Number of subjects: 50
Study 9574454 — intervention group
Group type: COMPARATOR
Intervention: Creatinine clearance (CCr) predicted according to the Cockcroft and Gault formula
Number of subjects: 50
Study 9574454 — intervention group
Group type: COMPARATOR
Intervention: Conventional method by collecting 24 h urine
Number of subjects: 50
Study 7920977 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (lipid-supplemented solution)
Number of subjects: 26
Study 7920977 — intervention group
Group type: COMPARATOR
Intervention: Group I (predominantly carbohydrate solution)
Number of subjects: 26
Study 30947825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 102
Study 30947825 — intervention group
Group type: COMPARATOR
Intervention: Landmark-based injection
Number of subjects: 102
Study 28961996 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-containing regimens
Number of subjects: 2339
Study 28961996 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin triple therapy
Number of subjects: 2339
Study 28961996 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakpoint of amoxicillin resistance ≥0.125 mg/L
Number of subjects: 2339
Study 26272173 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin detemir
Number of subjects: 12
Study 26272173 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 12
Study 23292848 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric resistance training (ECC)
Number of subjects: 34
Study 23292848 — intervention group
Group type: COMPARATOR
Intervention: Concentric resistance training (CON)
Number of subjects: 34
Study 20501520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg/h)
Number of subjects: 0
Study 20501520 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.3 μg/kg/min)
Number of subjects: 0
Study 20501520 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Dexmedetomidine and Remifentanil)
Number of subjects: 0
Study 18327852 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs)
Number of subjects: 0
Study 18327852 — intervention group
Group type: COMPARATOR
Intervention: ACEI therapy
Number of subjects: 0
Study 17144553 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular contrapulsation (MCP) alone
Number of subjects: 0
Study 17144553 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular contrapulsation (MCP) in combination with balneotherapy (radon and iodine-bromine baths)
Number of subjects: 0
Study 14658990 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic approach to treatment including patient education, encouragement of exposure, attention to relevant comorbidities, use of empirically proven pharmacotherapies, and psychosocial interventions of adequate intensity and duration.
Number of subjects: 0
Study 10718785 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride in the fed state (high-fat meal)
Number of subjects: 30
Study 10718785 — intervention group
Group type: COMPARATOR
Intervention: Azimilide dihydrochloride in the fasted state
Number of subjects: 30
Study 8736458 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for 1 month
Number of subjects: 41
Study 1550474 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oral intake 4 hours after removal of the tube
Number of subjects: 171
Study 1550474 — intervention group
Group type: COMPARATOR
Intervention: Ordinary solid intake soon after nasogastric tube removal
Number of subjects: 171
Study 1550474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study 3875296 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg bwxh nimodipine
Number of subjects: 64
Study 3875296 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg bwxh nimodipine
Number of subjects: 64
Study 3875296 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of nimodipine
Number of subjects: 64
Study 3875296 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% NaCl as placebo)
Number of subjects: 64
Study 31502749 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg
Number of subjects: 71
Study 31502749 — intervention group
Group type: COMPARATOR
Intervention: dapagliflozin 10 mg
Number of subjects: 71
Study 31502749 — intervention group
Group type: COMPARATOR
Intervention: gemigliptin 50 mg and dapagliflozin 10 mg
Number of subjects: 71
Study 30314512 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eye movement desensitization and reprocessing (EMDR) intervention performed by a trained psychologist during ER stay
Number of subjects: 446
Study 30314512 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 446
Study 30314512 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eye movement desensitization and reprocessing (EMDR) intervention
Number of subjects: 446
Study 27018153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial allergen
Number of subjects: 18
Study 27018153 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE)
Number of subjects: 18
Study 24607365 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence, Methadone & Work Reinforcement
Number of subjects: 98
Study 24607365 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone & Work Reinforcement
Number of subjects: 98
Study 24607365 — intervention group
Group type: COMPARATOR
Intervention: Work Reinforcement
Number of subjects: 98
Study 22491353 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 19
Study 22491353 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion (diphenhydramine)
Number of subjects: 19
Study 22491353 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-induced anhedonic symptoms
Number of subjects: 19
Study 20410913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 or 3 g day(‐1) plus oral corticosteroids
Number of subjects: 96
Study 20410913 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral corticosteroids
Number of subjects: 96
Study 20410913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 96
Study 18848429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐MTEE imaging of prosthetic MVs and annuloplasty rings
Number of subjects: 87
Study 18848429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐MTEE imaging
Number of subjects: 87
Study 15823285 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat 120 mg plus a moderate-fat meal (MFO)
Number of subjects: 10
Study 15823285 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat 120 mg plus a high-fat meal (HFO)
Number of subjects: 10
Study 15823285 — intervention group
Group type: COMPARATOR
Intervention: placebo plus a high-fat meal (HFP)
Number of subjects: 10
Study 12433452 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol dry powder formulations (50 microg to 400 microg)
Number of subjects: 12
Study 12433452 — intervention group
Group type: EXPERIMENTAL
Intervention: MSLI or ACI impactors for in vitro testing
Number of subjects: 12
Study 12433452 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalence testing criteria
Number of subjects: 12
Study 10526025 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage management (Group A): Preoperative endoscopic retrograde cholangiography (ERC) with endoscopic stone extraction (ESE) followed by laparoscopic cholecystectomy (LC) during the same hospital admission.
Number of subjects: 300
Study 10526025 — intervention group
Group type: COMPARATOR
Intervention: Single-stage laparoscopic management (Group B): Single-stage laparoscopic treatment.
Number of subjects: 300
Study 8719512 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine (acellular pertussis vaccine containing pertussis toxoid, filamentous hemagglutinin, and pertactin)
Number of subjects: 557
Study 8719512 — intervention group
Group type: COMPARATOR
Intervention: DTP-Connaught (whole-cell pertussis vaccine)
Number of subjects: 557
Study 8719512 — intervention group
Group type: COMPARATOR
Intervention: DTP-Lederle (whole-cell pertussis vaccine)
Number of subjects: 557
Study 2200826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg once weekly
Number of subjects: 24
Study 2200826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6117309 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride 400 mg
Number of subjects: 8
Study 6117309 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg + Hydralazine 25 mg or 50 mg
Number of subjects: 8
Study 30973344 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered computerized cognitive behavioral therapy (ICBT) plus usual care (UC)
Number of subjects: 23
Study 30973344 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 23
Study 30973344 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT plus UC
Number of subjects: 23
Study 29152825 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT + CRT
Number of subjects: 30
Study 29152825 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT + AT
Number of subjects: 30
Study 29152825 — intervention group
Group type: COMPARATOR
Intervention: FBT
Number of subjects: 30
Study 26945478 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness instructions
Number of subjects: 319
Study 26945478 — intervention group
Group type: COMPARATOR
Intervention: Distraction control instructions
Number of subjects: 319
Study 26945478 — intervention group
Group type: COMPARATOR
Intervention: No-instruction control conditions
Number of subjects: 319
Study 24766337 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongyloides stercoralis infection
Number of subjects: 149
Study 24766337 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without S. stercoralis larvae)
Number of subjects: 149
Study 22126282 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus systemic amoxicillin (500 mg) and metronidazole (400 mg) 3 times a day for 14 days
Number of subjects: 24
Study 22126282 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 24
Study 20881664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized nebulization of amphotericin B lipid complex at 1 mg/kg every 24 hr for 4 days
Number of subjects: 35
Study 18981770 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir [400/100 mg twice a day (LPV/r)]
Number of subjects: 140
Study 18981770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir [500/200 mg twice a day (TPV/r200)]
Number of subjects: 140
Study 18981770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir [500/100 mg twice a day (TPV/r100)]
Number of subjects: 140
Study 15799981 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-directed voucher
Number of subjects: 1394
Study 15799981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nurse intervention and consumer-directed voucher
Number of subjects: 1394
Study 15799981 — intervention group
Group type: COMPARATOR
Intervention: Disease-management-health-promotion nurse intervention
Number of subjects: 1394
Study 12750967 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1 + Filtek Flow
Number of subjects: 0